A new antiviral drug has been reported in a study that researchers believe has high clinical potential as a next-generation influenza drug.
List view / Grid view
Filter the results
In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered.
A machine-learning algorithm has been created that automates high-throughput screens of epigenetic medicines.
22 October 2019 | By Halo Labs
Aqueous solubility of small molecule compounds is an essential parameter during the hit-to-lead stage of drug discovery as well as lead optimization and formulation. Low solubility can result in misleading ADMET/DMPK analyses if some fraction of a compound precipitates. Register now to find out more!
A drug discovery platform for mental health treatment could also help to identify mechanisms for the treatment of substance use disorders.
New protein-painting technology could lead to developing cancer immunotherapy medicines that can be administered as a pill.
Researchers have imaged an inflammation-related protein receptor on cell membranes which could inform future drug designs to prevent cell death.
A new process for identifying and biosynthesising drug candidates has been discovered by researchers at the Carl R Woese Institute for Genomic Biology.
The process that bacteria use to defend themselves has been revealed by researchers, who also demonstrated how to activate the process.
A study using high-throughput screening has revealed some promising compounds that could be used in future cancer treatments.
A team has discovered that fungi use the Diels-Alder reaction to assemble new compounds that have potential pharmaceutical uses.
The memory of mice with Alzheimer's greatly improved after they were injected with two newly discovered short peptides.
Currently, there is no licensed treatment to slow or stop the progression of Parkinson’s disease. However, a team at Sheffield University in the UK are currently working to identify compounds that target the dopaminergic brain cells affected by the disease. Nikki Withers speaks to Dr Heather Mortiboys to hear how…
Vernalis Research is based at Granta Park in Cambridge, UK and specialises in the development and application of fragment- and structure-based drug discovery methods. Nikki Withers met with Vernalis’ Research Director, James Murray, to discuss the company’s innovative approach to target discovery and how they sustain symbiotic collaborations to progress…
Steven van Helden, Chief Technology Officer at Pivot Park Screening Centre (PPSC), relies on efficient microplate readers for effective hit discovery.
We are on the precipice of realising the true potential of genomics studies. Following completion of the Human Genome Project six years ago, huge strides have been made in understanding how the genome works, shedding light on disease pathogenesis and forging therapeutic efforts. In this article, Pushpanathan Muthuirulan explains how…